IDEXX Laboratories (NASDAQ:IDXX)‘s stock had its “sell” rating reissued by stock analysts at Aegis in a report released on Friday.

A number of other equities research analysts have also recently weighed in on IDXX. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective for the company in a research note on Tuesday, October 24th. Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 target price on shares of IDEXX Laboratories in a research report on Tuesday, October 24th. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 target price on shares of IDEXX Laboratories in a research report on Friday, October 6th. Finally, Bank of America raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 target price on the stock in a research report on Wednesday, August 23rd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $173.67.

Shares of IDEXX Laboratories (NASDAQ IDXX) opened at $159.70 on Friday. The stock has a market capitalization of $14,004.71, a P/E ratio of 54.06, a price-to-earnings-growth ratio of 2.43 and a beta of 0.42. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48. IDEXX Laboratories has a 12 month low of $113.92 and a 12 month high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.05. The company had revenue of $492.00 million for the quarter, compared to the consensus estimate of $492.94 million. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. IDEXX Laboratories’s quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.62 EPS. sell-side analysts expect that IDEXX Laboratories will post 3.24 earnings per share for the current year.

In other news, insider Giovani Twigge sold 2,000 shares of IDEXX Laboratories stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $156.07, for a total value of $312,140.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jonathan W. Ayers sold 18,000 shares of IDEXX Laboratories stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $153.75, for a total value of $2,767,500.00. Following the completion of the sale, the chief executive officer now directly owns 1,064,573 shares of the company’s stock, valued at $163,678,098.75. The disclosure for this sale can be found here. In the last quarter, insiders have sold 110,000 shares of company stock worth $16,686,200. 2.77% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IDXX. WMS Partners LLC grew its holdings in shares of IDEXX Laboratories by 0.3% in the 2nd quarter. WMS Partners LLC now owns 1,583 shares of the company’s stock worth $256,000 after acquiring an additional 4 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in shares of IDEXX Laboratories by 0.3% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,547 shares of the company’s stock worth $1,057,000 after acquiring an additional 19 shares during the period. Strs Ohio grew its holdings in shares of IDEXX Laboratories by 0.7% in the 2nd quarter. Strs Ohio now owns 5,929 shares of the company’s stock worth $957,000 after acquiring an additional 41 shares during the period. National Asset Management Inc. lifted its stake in IDEXX Laboratories by 2.1% in the 2nd quarter. National Asset Management Inc. now owns 2,051 shares of the company’s stock valued at $332,000 after buying an additional 42 shares in the last quarter. Finally, Advisor Group Inc. lifted its stake in IDEXX Laboratories by 1.1% in the 2nd quarter. Advisor Group Inc. now owns 4,998 shares of the company’s stock valued at $732,000 after buying an additional 52 shares in the last quarter. Institutional investors own 86.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/12/aegis-reiterates-sell-rating-for-idexx-laboratories-idxx.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Analyst Recommendations for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Stock Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related stocks with our FREE daily email newsletter.